Christos Psarrakis, Nikolaos-Renatos Tziolos, Vicky Matzarakis, Vinod Kumar, Emmanouil Stylianakis, Chrysanthi Sidiropoulou, Elisavet Tasouli, Konstantina Iliopoulou, Michael Samarkos, Symeon Metallidis, Sarah Georgiadou, Karolina Akinosoglou, Amalia Bolanou, Erifli Hatziagelaki, Alina Kostaki, Periklis Panagopoulos, Konstantinos Toutouzas, Haralarampos Milionis, Georgios Adamis, Garyfallia Poulakou, Malvina Lada, Athanasios Skoutelis, Zoi Alexiou, Styliani Symbardi, George Chrysos, Mihai G. Netea, Evangelos J. Giamarellos-Bourboulis

Cell Reports Medicine, January 2, 2026
DOI: 10.1016/j.xcrm.2025.102533Download pdf 🡇

Funding

The study was funded in part by the Hellenic Institute for the Study of Sepsis, Astellas, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. Rahway, NJ, USA. The funders did not have any role in study designs, data analysis, interpretation of the data, and decision to publish. All authors approved the final version of the article, including the authorship list.

Keywords:  Clostridioides difficile; bezlotoxumab; single-nucleotide polymorphisms; microbiome

Related study: BEYOND